Silvy Lachance

Montreal, QC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Risk factors for EBV reactivation and impact of graft composition following GVHD prophylaxis with rabbit ATG or PTCy.

Risk factors for EBV reactivation and impact of graft composition following GVHD prophylaxis with rabbit ATG or PTCy.

Journal: Bone marrow transplantation

Published: January 21, 2026

Tumor flare pain reaction following bispecific T-Cell engagers in multiple myeloma: a unique and underrecognized toxicity.

Tumor flare pain reaction following bispecific T-Cell engagers in multiple myeloma: a unique and underrecognized toxicity.

Journal: Haematologica

Published: September 07, 2025

Comparison of Outcomes after UM171-Expanded Cord Blood and Six Conventional Donor Source Transplants: A Matched Analysis from the EBMT Registry.

Comparison of Outcomes after UM171-Expanded Cord Blood and Six Conventional Donor Source Transplants: A Matched Analysis from the EBMT Registry.

Journal: Transplantation and cellular therapy

Published: June 10, 2025

Management of liver sinusoidal obstruction syndrome/veno-occlusive disease in adults: a 2025 perspective from an international expert group.

Management of liver sinusoidal obstruction syndrome/veno-occlusive disease in adults: a 2025 perspective from an international expert group.

Journal: Bone marrow transplantation

Published: March 09, 2025

Enhancing CAR-T Efficacy in Large B-Cell Lymphoma with Radiation Bridging Therapy: A Real-World Single-Center Experience.

Enhancing CAR-T Efficacy in Large B-Cell Lymphoma with Radiation Bridging Therapy: A Real-World Single-Center Experience.

Journal: Current oncology (Toronto, Ont.)

Published: January 05, 2025

A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell Transplant.

A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell Transplant.

Journal: Current oncology (Toronto, Ont.)

Published: September 20, 2024

A Pilot Study of UM171-Expanded Cord Blood Grafts for Tandem Auto/Allogeneic Hematopoietic Cell Transplant in High and Ultra-High-Risk Myeloma Patients.

A Pilot Study of UM171-Expanded Cord Blood Grafts for Tandem Auto/Allogeneic Hematopoietic Cell Transplant in High and Ultra-High-Risk Myeloma Patients.

Journal: Transplantation and cellular therapy

Published: July 07, 2024

Improved outcomes of UM171-expanded cord blood transplantation compared with other graft sources: real-world evidence.

Improved outcomes of UM171-expanded cord blood transplantation compared with other graft sources: real-world evidence.

Journal: Blood advances

Published: May 01, 2023

Bortezomib Maintenance After Allogeneic Transplantation in Newly Diagnosed Myeloma Patients Results in Decreased Incidence and Severity of Chronic GVHD.

Bortezomib Maintenance After Allogeneic Transplantation in Newly Diagnosed Myeloma Patients Results in Decreased Incidence and Severity of Chronic GVHD.

Journal: Transplantation and cellular therapy

Published: August 23, 2022

Two types of human TCR differentially regulate reactivity to self and non-self antigens.

Two types of human TCR differentially regulate reactivity to self and non-self antigens.

Journal: iScience

Published: April 27, 2022

Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment.

Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment.

Journal: Blood reviews

Published: April 01, 2022

Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study.

Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study.

Journal: Bone marrow transplantation

Published: August 29, 2021

Showing 1-12 of 34

Last Updated: 09/26/2026